ABSTRACT
Historically, the US military has utilized centralized store-and-forward (S&F) telemedicine programs for health care providers in remote locations worldwide. In the civilian community, new methods and platforms for teledermatology have been created based largely on those used by the military to maximize access to and the efficiency of health care, including secure direct-to-consumer (DTC) mobile applications for patients, live interactive methods, and integrated S&F platforms for dermatology services within electronic health record (EHR) systems. By incorporating similar innovative teledermatology methods and platforms, the US military health care system may benefit from increased accessibility and productivity.
Subject(s)
Telemedicine/history , Dermatology , History, 20th Century , History, 21st Century , Humans , Military Medicine , Telemedicine/trends , United StatesSubject(s)
Encephalitis, Varicella Zoster/diagnosis , Folliculitis/diagnosis , Herpes Zoster/diagnosis , Herpesvirus 3, Human , Opportunistic Infections/diagnosis , Skin Diseases, Papulosquamous/diagnosis , Biopsy , Folliculitis/pathology , Hair Follicle/pathology , Humans , Keratinocytes/pathology , Lymphoma, B-Cell/complications , Male , Middle AgedABSTRACT
BACKGROUND: Melkersson-Rosenthal syndrome is an unusual cause of facial swelling that can be confused with angioedema. OBJECTIVE: To describe a young woman with facial swelling initially considered to be angioedema. METHODS: A biopsy specimen of the eyelid demonstrated findings consistent with Melkersson-Rosenthal syndrome. RESULTS: After reviewing the differential diagnosis of pseudoangioedema, a presumptive diagnosis of Melkersson-Rosenthal syndrome was made. The patient was successfully treated with infliximab for Melkersson-Rosenthal syndrome. Owing to medication adverse effects, infliximab treatment was discontinued. Treatment was then continued with adalimumab, with good effect and without adverse events. CONCLUSIONS: We report the case of a patient with Melkersson-Rosenthal syndrome presenting as angioedema. Furthermore, we report the first successful treatment of Melkersson-Rosenthal syndrome with adalimumab.
